Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Release Date: November 26, 2025

Expiration Date: November 26, 2026

Activity Overview

This Community Practice Connection™ program provides an in-depth review of some highlights from the 2025 Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice. This unique and engaging multimedia activity is ideal for community-based clinicians and focuses on the practical aspects of using DLL3-targeted bispecific T-cell engager therapy to manage patients with small cell lung cancer (SCLC), helping clinicians to place recent clinical trial data into context. The program is designed for those who did not attend the live program and to help reinforce learnings for those who did.

Target Audience

This educational program is primarily directed toward community-based oncologists and other health care providers involved in the treatment of SCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the rationale and mechanism of actions for emerging DLL3-targeted agents, including bispecific antibodies, antibody drug conjugates, and chimeric antigen receptor T-cell therapies
• Evaluate the latest trial data on DLL3-targeting therapies in SCLC
• Implement care plans to monitor and mitigate common adverse effects of DLL3-targeted therapies using evidence-based management approaches
• Apply strategies to effectively coordinate care between the community cancer and academic centers